基于网络药理学及动物实验探讨苗药地锦草抗肝纤维化的作用机制OA
Exploring the Mechanism of Miao Medicine Euphorbia humifusa Against Liver Fibrosis Based on Network Pharmacology and Animal Experiments
目的 基于网络药理学及动物实验探讨苗药地锦草抗肝纤维化的作用机制.方法 (1)通过中药系统药理学分析平台(TCMSP)筛选获取地锦草活性成分及其作用靶点;通过GeneCard、PharmGkb、OMIM、TTD 数据库检索肝纤维化疾病相关靶点;对地锦草活性成分作用靶点与肝纤维化疾病相关靶点取交集,得到地锦草治疗肝纤维化的潜在作用靶点.将地锦草活性成分、潜在作用靶点导入Cytoscape 3.7.2 软件,构建"有效成分-靶点"关系网络;通过STRING数据库构建潜在作用靶点的蛋白互作(PPI)网络;对地锦草治疗肝纤维化的潜在作用靶点进行GO功能及KEGG通路富集分析.(2)将SD大鼠随机分为空白组(7 只)、模型组(7 只)、水飞蓟宾组(6 只)及地锦草低、中、高剂量组(各 6 只).大鼠腹腔注射四氯化碳-橄榄油混合液(体积比为 2∶3),注射剂量为 3 mL·kg-1,每周注射 2 次,连续注射 8 周,复制肝纤维化大鼠模型.地锦草低、中、高剂量分别为0.675、1.35、2.70 g·kg-1,水飞蓟宾剂量为 18.9 mg·kg-1,各组灌胃给药体积为 10 mL·kg-1,每日 1 次,连续30 d.采用HE及Masson染色法观察大鼠肝脏组织病理变化;免疫组化法检测肝脏组织中α-平滑肌肌动蛋白(α-SMA)、转化生长因子β1(TGF-β1)表达水平;ELISA法测定血清Ⅲ型前胶原蛋白(PCⅢ)、层粘连蛋白(LN)、透明质酸(HA)、Ⅳ型胶原酶(Col Ⅳ)水平;Western Blot及qRT-PCR法检测大鼠肝脏组织缺氧诱导因子1α(HIF-1α)、血管内皮生长因子A(VEGFA)蛋白及mRNA表达水平.结果 (1)共得到地锦草治疗肝纤维化的潜在作用靶点(交集靶点)147 个.PTGS2、HSP90AA1、AR、GSTP1、TNF、HIF1A、PGR等潜在作用靶点与鞣花酸、谷甾醇、槲皮素、恩沙库林、山柰酚、5,4'-二羟基黄酮等活性成分关系密切.TP53、HSP90AA1、AKT1、TNF、IL6、RELA、HIF1A等靶点可能是地锦草治疗肝纤维化的核心靶点.地锦草治疗肝纤维化的潜在作用靶点主要富集在AGE-RAGE通路、IL-17 信号通路、TNF通路、HIF-1 通路等.(2)与空白组比较,模型组大鼠肝细胞排列紊乱,肝细胞水肿,汇管区大量结缔组织增生,间质内有炎性细胞浸润;明显可见蓝色胶原纤维沉积及纤维间隔,纤维面积占比明显升高(P<0.01);肝脏组织α-SMA、TGF-β1 表达量显著升高(P<0.05,P<0.01);血清PCⅢ、LN、HA、Col IV水平均显著升高(P<0.01);肝脏组织HIF-1α、VEGFA蛋白及mRNA表达显著上调(P<0.01).与模型组比较,各给药组大鼠肝脏组织在炎性细胞浸润、结缔组织增生、肝细胞水肿等方面均有不同程度改善,水飞蓟宾组及地锦草高剂量组的纤维面积占比明显降低(P<0.05,P<0.01);水飞蓟宾组及地锦草中、高剂量组大鼠肝脏组织α-SMA、TGF-β1 表达量显著降低(P<0.05,P<0.01);各给药组大鼠血清PCⅢ、LN、HA、Col IV水平均显著降低(P<0.01),肝脏组织HIF-1α、VEGFA蛋白及mRNA表达显著下调(P<0.05,P<0.01).结论 苗药地锦草能够改善肝纤维化大鼠肝脏组织的病理损伤,减少胶原纤维沉积,可能与通过HIF-1α/VEGF通路对缺氧及新生血管的调控作用有关.
Objective To explore the mechanism of the Miao medicine Euphorbia humifusa against liver fibrosis based on network pharmacology and animal experiments.Methods(1)Active components of Euphorbia humifusa and their corresponding targets were screened and obtained through the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP).Disease-related targets for liver fibrosis were retrieved from the GeneCard,PharmGkb,OMIM,and TTD databases.The intersection of active component targets and disease targets yielded potential therapeutic targets of Euphorbia humifusa for liver fibrosis.The active components and potential targets were imported into Cytoscape 3.7.2 software to construct an"active component-target"network.A protein-protein interaction(PPI)network of potential targets was constructed using the STRING database.Gene Ontology(GO)functional enrichment and Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway analyses were performed on the potential therapeutic targets.(2)A liver fibrosis rat model was established by intraperitoneal injection of a carbon tetrachloride-olive oil mixture(volume ratio 2∶3)at a dose of 3 mL·kg-1,twice weekly for 8 consecutive weeks.SD rats were randomly divided into a blank group(n=7),model group(n=7),silibinin group(n=6),and low-,medium-,and high-dose Euphorbia humifusa groups(n=6 each).The doses for the low-,medium-,and high-dose Euphorbia humifusa groups were 0.675,1.35,and 2.70 g·kg-1,respectively,and the silibinin dose was 18.9 mg·kg-1.All drugs were administered intragastrically at a volume of 10 mL·kg-1 once daily for 30 days.Liver tissue pathological changes were observed by HE and Masson staining.The expression levels of α-SMA and TGF-β1 in liver tissue were detected by immunohistochemistry.Serum levels of procollagen type III(PC III),laminin(LN),hyaluronic acid(HA),and collagen type Ⅳ(Col Ⅳ)were measured by ELISA.The protein and mRNA expression levels of HIF-1α and VEGF in liver tissue were detected by Western Blot and qRT-PCR,respectively.Results(1)A total of 147 potential therapeutic targets(intersection targets)for Euphorbia humifusa against liver fibrosis were obtained.Potential targets such as PTGS2,HSP90AA1,AR,GSTP1,TNF,HIF1A,and PGR were closely associated with active components including ellagic acid,sitosterol,quercetin,ensaculin,kaempferol,and 5,4'-dihydroxyflavone.Targets such as TP53,HSP90AA1,AKT1,TNF,IL6,RELA,and HIF1A may be the core targets for Euphorbia humifusa in treating liver fibrosis.The potential therapeutic targets were mainly enriched in pathways including the AGE-RAGE signaling pathway,IL-17 signaling pathway,TNF signaling pathway,and HIF-1 signaling pathway.(2)Compared with the blank group,the model group showed disordered arrangement of hepatocytes,hepatocyte edema,extensive connective tissue proliferation in the portal area,and inflammatory cell infiltration in the interstitium;significant blue collagen fiber deposition and fibrous septa were visible,and the fibrous area ratio was significantly increased(P<0.01);the expression levels of α-SMA and TGF-β1 in liver tissue were significantly elevated(P<0.05,P<0.01);serum levels of PC Ⅲ,LN,HA,and Col Ⅳ were all significantly increased(P<0.01);and the protein and mRNA expression of HIF-1α and VEGFA in liver tissue were significantly upregulated(P<0.01).Compared with the model group,all treatment groups showed varying degrees of improvement in inflammatory cell infiltration,connective tissue proliferation,and hepatocyte edema in liver tissue.The fibrous area ratio was significantly reduced in the silibinin group and the high-dose Euphorbia humifusa group(P<0.05,P<0.01);the expression levels of α-SMA and TGF-β1 in liver tissue were significantly decreased in the silibinin group and the medium-and high-dose Euphorbia humifusa groups(P<0.05,P<0.01);serum levels of PC Ⅲ,LN,HA,and Col Ⅳ were significantly reduced in all treatment groups(P<0.01);and the protein and mRNA expression of HIF-1α and VEGFA in liver tissue were significantly downregulated(P<0.05,P<0.01).Conclusion The Miao medicine Euphorbia humifusa can ameliorate pathological damage and reduce collagen fiber deposition in the liver tissue of rats with liver fibrosis,which may be related to its regulatory effect on hypoxia and angiogenesis via the HIF-1α/VEGF pathway.
文维农;安祯祥;何远利;吴闵;何松
贵州中医药大学第一临床医学院,贵州 贵阳 550001贵州中医药大学第一临床医学院,贵州 贵阳 550001||贵州中医药大学第一附属医院,贵州 贵阳 550001贵州中医药大学第一临床医学院,贵州 贵阳 550001||贵州中医药大学第一附属医院,贵州 贵阳 550001贵州中医药大学第一临床医学院,贵州 贵阳 550001贵州中医药大学第一临床医学院,贵州 贵阳 550001||贵州中医药大学第一附属医院,贵州 贵阳 550001
医药卫生
苗药地锦草肝纤维化网络药理学HIF-1α/VEGF通路缺氧血管生成大鼠
Miao medicineEuphorbia humifusaliver fibrosisnetwork pharmacologyHIF-1α/VEGF pathwayhypoxiaangiogenesisrats
《中药新药与临床药理》 2026 (2)
277-286,10
国家自然科学基金项目(82160893,81760865)国家中医药管理局第五批全国中医临床优秀人才研修项目(国中医药人教函[2022]1号)贵州中医药大学中医脾胃病科技创新人才团队建设(贵中医TD[2022]005号)贵州省中医药管理局中医药、民族医药科学技术研究项目(QZYY-2024-014)贵州省卫生健康委科学技术基金项目(gzwkj2024-120).
评论